A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC

Introduction: Although immune checkpoint inhibitors (ICIs) have dramatically improved outcomes for nononcogene-addicted NSCLC, monotherapy with programmed cell death protein-1 (PD1) inhibition has been associated with low efficacy in the EGFR-mutant setting. Given the potential for synergism with co...

Full description

Bibliographic Details
Main Authors: Gillianne G.Y. Lai, MBBS, Jia Chi Yeo, PhD, Amit Jain, MBBS, PhD, Siqin Zhou, MSc, Mengyuan Pang, MSc, Jacob J.S. Alvarez, BSc, Ngak Leng Sim, BCS, Aaron C. Tan, MBBS, FRACP, PhD, Lisda Suteja, BSc, Tze Wei Lim, BSc, Yu Amanda Guo, PhD, Meixin Shen, PhD, Stephanie P.L. Saw, MBBS, Neha Rohatgi, BSc, Joe P.S. Yeong, MBBS, PhD, Angela Takano, MBBS, Kiat Hon Lim, MBBS, Apoorva Gogna, MBBS, Chow Wei Too, MBBS, Kun Da Zhuang, MBBS, Wan Ling Tan, MBBS, Ravindran Kanesvaran, MBBS, Quan Sing Ng, MBBS, Mei Kim Ang, MBBS, Tanujaa Rajasekaran, MBBS, Lanying Wang, MBBS, Chee Keong Toh, MBBS, Wan-Teck Lim, MBBS, Wai Leong Tam, PhD, Sze Huey Tan, PhD, Anders M.J. Skanderup, PhD, Eng-Huat Tan, MBBS, Daniel S.W. Tan, BSc, MBBS, MRCP, PhD
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:JTO Clinical and Research Reports
Subjects:
Lung cancer
Epidermal growth factor receptor
Immunotherapy
Biomarkers
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001400

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001400

Similar Items